The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signalling Pathways Is a Means to an End

Cancer is a fatal genetic disease involving unregulated cell growth and proliferation with varying underlying complexities that require carefully optimized treatment for a full cure. It necessitates effective targeting of dysregulated signaling pathways involving growth factors, regulatory proteins, cell adhesion molecules, and molecules of the immune system, mainly driven by alterations in tumor suppressor genes and oncogenes that may vary among different cancer types. Importantly, patients with the same cancer type respond differently to available cancer treatments, likely due to tumor-specific DNA, RNA, and proteins, indicating the need for patient-specific treatment options. Precision oncology has evolved as a form of cancer therapy focused on genetic and molecular profiling of tumors to identify specific molecular alterations involved in carcinogenesis for tailored individualized cancer treatment. The application of multi-omics technologies, including single-cell multi-omics, constitutes a novel approach for the identification and quantification of a comprehensive set of biological molecules and to study how they translate into cellular functions and tissue pathologies, which is crucial for precision oncology. Additionally, the role of computational techniques to analyze complex data and identify patterns of disease development to improve outcomes is now well established in medical oncology. This article aims to briefly explain the foundations and frontiers of precision oncology in the context of cutting-edge innovations in tools and techniques associated with the process to assess its scope and importance in achieving the intended goals over time.